US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications
Executive Summary
Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.
You may also be interested in...
Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record
New oncologics bring CDER’s novel agent approvals count to 53 for the year.
US FDA Outlines Streamlined Development Path For Targeted Therapies
But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.
Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications
Accelerated approval for patients with microsatellite instability-high or mismatch repair deficient solid tumors is the first time the US FDA has granted an indication that does not specify the location of the tumor – a change precision medicine researchers have been eager to make.